论文部分内容阅读
目的评价莫西沙星对下呼吸道感染的疗效和安全性。方法轻中度下呼吸道感染者120例随机分成两组,莫西沙星组62例给予莫西沙星0.4g,静脉滴注(住院),门诊0.4g(口服)均1次/d,洛美沙星组58例予0.4g静脉滴注,1次/d。两组均以7~14d为1个疗程。结果莫西沙星与洛美沙星的临床有效率分别是91.9%、89.7%(P>0.05),细菌消除率分别为89.8%、88.9%(P>0.05),两组无明显不良反应。结论莫西沙星对下呼吸道感染的治疗是安全和有效的。
Objective To evaluate the efficacy and safety of moxifloxacin in lower respiratory tract infection. Methods One hundred and twenty patients with mild to moderate lower respiratory tract infection were randomly divided into two groups. Moxifloxacin group (n = 62) was given moxifloxacin 0.4g, intravenous drip (hospitalized), outpatient 0.4g (oral) Group 58 cases were given 0.4g intravenous infusion, 1 time / d. Both groups were 7 ~ 14d for a course of treatment. Results The clinical effective rates of moxifloxacin and lomefloxacin were 91.9% and 89.7%, respectively (P> 0.05). The rates of bacterial elimination were 89.8% and 88.9% respectively (P> 0.05). There was no significant adverse reaction in both groups. Conclusion Moxifloxacin is safe and effective for the treatment of lower respiratory tract infections.